- Home
- CLLS vs ARL Comparison
CLLS vs ARL Comparison
Compare CLLS & ARL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- ARL
- Stock Information
- Founded
- CLLS 1999
- ARL 1999
- Country
- CLLS France
- ARL United States
- Employees
- CLLS N/A
- ARL N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- ARL Building operators
- Sector
- CLLS Health Care
- ARL Real Estate
- Exchange
- CLLS Nasdaq
- ARL Nasdaq
- Market Cap
- CLLS 143.4M
- ARL 233.2M
- IPO Year
- CLLS 2007
- ARL N/A
- Fundamental
- Price
- CLLS $1.59
- ARL $14.52
- Analyst Decision
- CLLS Buy
- ARL
- Analyst Count
- CLLS 1
- ARL 0
- Target Price
- CLLS $4.00
- ARL N/A
- AVG Volume (30 Days)
- CLLS 48.9K
- ARL 3.8K
- Earning Date
- CLLS 08-05-2025
- ARL 08-07-2025
- Dividend Yield
- CLLS N/A
- ARL N/A
- EPS Growth
- CLLS N/A
- ARL N/A
- EPS
- CLLS N/A
- ARL N/A
- Revenue
- CLLS $54,747,000.00
- ARL $48,234,000.00
- Revenue This Year
- CLLS $48.52
- ARL N/A
- Revenue Next Year
- CLLS $5.17
- ARL N/A
- P/E Ratio
- CLLS N/A
- ARL N/A
- Revenue Growth
- CLLS 351.26
- ARL N/A
- 52 Week Low
- CLLS $1.10
- ARL $9.43
- 52 Week High
- CLLS $2.43
- ARL $22.77
- Technical
- Relative Strength Index (RSI)
- CLLS 56.98
- ARL 57.31
- Support Level
- CLLS $1.56
- ARL $13.22
- Resistance Level
- CLLS $1.49
- ARL $15.00
- Average True Range (ATR)
- CLLS 0.09
- ARL 0.59
- MACD
- CLLS 0.01
- ARL 0.01
- Stochastic Oscillator
- CLLS 80.00
- ARL 77.51
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About ARL American Realty Investors Inc.
American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments; the acquisition, development, ownership and management of multifamily properties (Residential); and the acquisition, development, ownership, and management of commercial properties (Commercial), which predominantly comprise office properties. Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.